Attention-deficit/Hyperactivity Disorder (ADHD) Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Analysis

Attention-deficit/Hyperactivity Disorder (ADHD) Emerging Therapies, Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Analysis

“Delveinsight Business Research LLP”
“Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/Hyperactivity Disorder (ADHD) Market.

The Attention-deficit/Hyperactivity Disorder (ADHD) Pipeline report embraces in-depth commercial and clinical assessment of the Attention-deficit/Hyperactivity Disorder (ADHD) pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ADHD collaborations, mergers, acquisition, funding, designations, and other product-related details.

Get FREE sample copy at:

As per DelveInsight, the Attention-deficit/Hyperactivity Disorder (ADHD) market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM. The launch of upcoming therapies will also boost the market growth. 

Attention-deficit/Hyperactivity Disorder (ADHD) Companies:

  • Shire

  • KemPharm

  • Tris Pharma

  • Arbor Pharma

  • Neos Therapeutics

  • Highland Therapeutics

  • Rhodes Pharmaceuticals

  • Supernus Pharmaceuticals

  • Otsuka Pharmaceuticals

  • Hisamitsu Pharmaceutical

And many others.

Attention-deficit/hyperactivity disorder (ADHD) Pipeline

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of ADHD with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the ADHD Treatment.

  • Attention-deficit/Hyperactivity Disorder (ADHD) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • ADHD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ADHD market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Attention-deficit/Hyperactivity Disorder (ADHD) Therapies covered in the report include:

  • KP415

  • KP484

  • SPN-812

  • Centanafadine

And many more.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for ADHD.    

  • In the coming years, the Attention-deficit/Hyperactivity Disorder (ADHD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence ADHD Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Attention-deficit/Hyperactivity Disorder (ADHD) treatment market. Several potential therapies for Attention-deficit/Hyperactivity Disorder (ADHD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the ADHD market size in the coming years.  

  • Our in-depth analysis of the ADHD pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Attention-deficit/Hyperactivity Disorder (ADHD) 

3. Attention-deficit/Hyperactivity Disorder (ADHD) Current Treatment Patterns

4. Attention-deficit/Hyperactivity Disorder (ADHD) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Attention-deficit/Hyperactivity Disorder (ADHD) Late Stage Products (Phase-III)

7. Attention-deficit/Hyperactivity Disorder (ADHD) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Attention-deficit/Hyperactivity Disorder (ADHD) Discontinued Products

13. Attention-deficit/Hyperactivity Disorder (ADHD) Product Profiles

14. Attention-deficit/Hyperactivity Disorder (ADHD) Key Companies

15. Attention-deficit/Hyperactivity Disorder (ADHD) Key Products

16. Dormant and Discontinued Products

17. Attention-deficit/Hyperactivity Disorder (ADHD) Unmet Needs

18. Attention-deficit/Hyperactivity Disorder (ADHD) Future Perspectives

19. Attention-deficit/Hyperactivity Disorder (ADHD) Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight –
Attention-deficit/Hyperactivity Disorder (ADHD) Market Insight
DelveInsight’s “Attention-deficit/Hyperactivity Disorder (ADHD) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Attention-deficit/Hyperactivity Disorder (ADHD) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). 

Cushing’s Syndrome Market
DelveInsight’ s “Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Cushing’s Syndrome market size, share, trends, growth, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States